Total Payments
$326,726
2024 Payments
$98,274
Companies
18
Transactions
143
Medicare Patients
5,670
Medicare Billing
$5.2M
Payment Breakdown by Category
Consulting$294,303 (90.1%)
Research$18,448 (5.6%)
Other$8,079 (2.5%)
Food & Beverage$3,266 (1.0%)
Travel$2,629 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $294,303 | 89 | 90.1% |
| Unspecified | $18,448 | 7 | 5.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,079 | 3 | 2.5% |
| Food and Beverage | $3,266 | 35 | 1.0% |
| Travel and Lodging | $2,629 | 9 | 0.8% |
Payments by Type
General
$308,277
136 transactions
Research
$18,448
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Research & Development, LLC | $69,950 | 14 | $0 (2023) |
| Astellas Pharma Global Development | $52,050 | 13 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $40,917 | 15 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $37,518 | 15 | $0 (2024) |
| F. Hoffmann-La Roche AG | $24,625 | 11 | $0 (2021) |
| Genentech, Inc. | $24,312 | 19 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $16,352 | 7 | $0 (2022) |
| Janssen Global Services, LLC | $16,087 | 17 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $11,052 | 2 | $0 (2023) |
| Ocular Therapeutix, Inc. | $11,044 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $98,274 | 44 | Boehringer Ingelheim International GmbH ($37,518) |
| 2023 | $42,254 | 19 | Astellas Pharma Global Development ($16,200) |
| 2022 | $64,345 | 25 | Apellis Pharmaceuticals, Inc. ($26,987) |
| 2021 | $12,862 | 5 | Alexion Pharmaceuticals, Inc. ($8,937) |
| 2020 | $21,173 | 6 | F. Hoffmann-La Roche AG ($16,948) |
| 2019 | $12,441 | 12 | Novartis Pharmaceuticals Corporation ($8,126) |
| 2018 | $10,051 | 12 | Genentech, Inc. ($6,132) |
| 2017 | $65,325 | 20 | Janssen Research & Development, LLC ($54,150) |
All Payment Transactions
143 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,432.50 | General |
| 12/19/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $477.50 | General |
| 12/18/2024 | Alcon Research LLC | AIR OPTIX (Device) | Food and Beverage | In-kind items and services | $148.36 | General |
| Category: Ophthalmology | ||||||
| 12/06/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| Category: Ophthalmology | ||||||
| 11/07/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| 10/30/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,865.00 | General |
| 10/30/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| Category: Ophthalmology | ||||||
| 10/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $950.00 | General |
| 10/18/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $300.00 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 10/02/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| Category: Ophthalmology | ||||||
| 09/17/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,058.75 | General |
| 09/13/2024 | Apellis Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,715.00 | General |
| 09/13/2024 | Astellas Pharma US Inc | Izervay (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Ophthalmology | ||||||
| 09/04/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| Category: Ophthalmology | ||||||
| 08/23/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,187.50 | General |
| 08/08/2024 | Alcon Research LLC | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 07/31/2024 | Astellas Pharma Global Development | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| Category: Ophthalmology | ||||||
| 06/07/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,425.00 | General |
| 06/06/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $950.00 | General |
| 06/04/2024 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $370.00 | General |
| 06/03/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $950.00 | General |
| 04/26/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $2,375.00 | General |
| 03/22/2024 | Regeneron Pharmaceuticals, Inc. | VEOPOZ (Biological) | Consulting Fee | Cash or cash equivalent | $940.00 | General |
| Category: RARE DISEASES | ||||||
| 03/22/2024 | Regeneron Pharmaceuticals, Inc. | VEOPOZ (Biological) | Consulting Fee | Cash or cash equivalent | $470.00 | General |
| Category: RARE DISEASES | ||||||
| 03/22/2024 | Regeneron Pharmaceuticals, Inc. | VEOPOZ (Biological) | Consulting Fee | Cash or cash equivalent | $470.00 | General |
| Category: RARE DISEASES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atropy Secondary to Age-Related Macular Degeneration | Astellas Pharma Global Development | $12,100 | 3 |
| STAIRWAY SIMULTANEOUS BLOCKADE OF ANGIOPOIETIN-2 AND VEGF-A WITH THE BISPECIFIC ANTIBODY RO6867461 RG7716 FOR EXTENDED DURABILITY IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | F. Hoffmann-La Roche AG | $3,384 | 2 |
| Check A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION, A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION | F. Hoffmann-La Roche AG | $1,004 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,462 | 21,376 | $4.0M | $1.4M |
| 2022 | 11 | 1,482 | 7,718 | $3.6M | $1.2M |
| 2021 | 11 | 1,427 | 4,747 | $3.5M | $1.3M |
| 2020 | 12 | 1,299 | 4,351 | $3.3M | $1.3M |
Total Patients
5,670
Total Services
38,192
Medicare Billing
$5.2M
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 78 | 948 | $1.4M | $650,576 | 47.6% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 44 | 17,520 | $1.3M | $510,243 | 40.7% |
| 67028 | Injection of drug into eye | Office | 2023 | 152 | 716 | $795,114 | $67,335 | 8.5% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 408 | 772 | $224,652 | $67,084 | 29.9% |
| J3490 | Unclassified drugs | Office | 2023 | 12 | 19 | $82,934 | $37,069 | 44.7% |
| 92134 | Imaging of retina | Office | 2023 | 262 | 636 | $109,392 | $18,033 | 16.5% |
| 92250 | Photography of the retina | Office | 2023 | 198 | 255 | $48,195 | $6,899 | 14.3% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 182 | 316 | $31,284 | $5,430 | 17.4% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 57 | 60 | $29,280 | $4,962 | 16.9% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 33 | 89 | $13,350 | $4,883 | 36.6% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 16 | 16 | $5,600 | $1,358 | 24.3% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 20 | 29 | $1,827 | $329.84 | 18.1% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 100 | 1,338 | $1.9M | $951,720 | 49.3% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 33 | 3,452 | $382,077 | $103,012 | 27.0% |
| 67028 | Injection of drug into eye | Office | 2022 | 133 | 727 | $799,992 | $67,321 | 8.4% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 397 | 757 | $220,287 | $66,526 | 30.2% |
| 92134 | Imaging of retina | Office | 2022 | 301 | 674 | $115,928 | $19,261 | 16.6% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2022 | 208 | 353 | $34,947 | $6,385 | 18.3% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 65 | 67 | $32,696 | $5,704 | 17.4% |
| 92250 | Photography of the retina | Office | 2022 | 164 | 196 | $37,044 | $5,067 | 13.7% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2022 | 29 | 89 | $13,350 | $4,639 | 34.7% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 25 | 25 | $8,750 | $2,090 | 23.9% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2022 | 27 | 40 | $2,520 | $460.95 | 18.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 112 | 1,490 | $2.1M | $1.1M | 49.8% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2021 | 11 | 317 | $185,128 | $79,838 | 43.1% |
About Eleonora Lad, MD, PHD
Eleonora Lad, MD, PHD is a Specialist healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/02/2008. The National Provider Identifier (NPI) number assigned to this provider is 1811150576.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Eleonora Lad, MD, PHD has received a total of $326,726 in payments from pharmaceutical and medical device companies, with $98,274 received in 2024. These payments were reported across 143 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($294,303).
As a Medicare-enrolled provider, Lad has provided services to 5,670 Medicare beneficiaries, totaling 38,192 services with total Medicare billing of $5.2M. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Ophthalmology, Retina Specialist
- Location Durham, NC
- Active Since 07/02/2008
- Last Updated 12/09/2022
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1811150576
Products in Payments
- CNTO 2476 (Biological) $54,150
- Izervay (Drug) $53,700
- Non-Covered Product (Drug) $15,294
- Lucentis (Biological) $12,211
- SUSVIMO (Drug) $8,635
- BEOVU (Drug) $4,550
- VEOPOZ (Biological) $1,880
- Syfovre (Drug) $1,727
- DEXTENZA (Drug) $300.00
- ForeseeHome (Device) $265.24
- EYLEA (Biological) $189.46
- AIR OPTIX (Device) $148.36
- OZURDEX (Drug) $124.18
- EYLEA HD (Biological) $124.14
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Durham
Dr. Wayne Dankner, Md, MD
Specialist — Payments: $109,248
Specialist $109,248
Dr. Elise Olsen, M.d, M.D
Specialist — Payments: $87,772
Specialist $87,772
Dr. Scott Cousins, Md, MD
Specialist — Payments: $51,140
Specialist $51,140
Dr. Brenna Hughes, M.d, M.D
Specialist — Payments: $16,136
Specialist $16,136
Dr. Joel Goodwin, M.d, M.D
Specialist — Payments: $13,734
Specialist $13,734
Dr. Aparna Rege, M.d, M.D
Specialist — Payments: $7,696
Specialist $7,696